{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:20:10Z","timestamp":1769041210561,"version":"3.49.0"},"reference-count":23,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Dysthyroid optic neuropathy (DON) is a sight-threatening complication of Graves\u2019 orbitopathy (GO). Treatment of DON consists of the urgent administration of intravenous methylprednisolone (ivMP) in very high doses followed by orbital decompression if the response is poor or absent. It is advised to continue the therapy with pulses of ivMP in a weekly schedule. The purpose of this study was to evaluate the impact of the additional treatment with ivMP in a 12-week protocol on visual acuity (VA), color vision, clinical activity score (CAS) and proptosis in patients with DON. Methods: This study was performed on 19 patients with DON (26 eyes) treated with ivMP in very high doses, with further orbital decompression in 11 individuals (15 eyes). VA, color vision, CAS and proptosis were evaluated prior to the DON treatment, before and after the 12-week ivMP (first and last pulse). Additionally follow up was performed (22 eyes). Results: VA and color vision improved between the first and last pulse of the additional ivMP treatment (p = 0.04 and p = 0.003, respectively). CAS and proptosis were reduced at the end of the 12-week ivMP therapy compared to observations at the beginning (p &lt; 0.001 and p = 0.04, respectively). Follow up confirmed stabilization of this achievement. Conclusions: The results of this study suggest that additional treatment with 12 pulses of ivMP improves or stabilizes the outcome of basic therapy in patients with DON.<\/jats:p>","DOI":"10.3390\/jcm11082068","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T13:39:51Z","timestamp":1649338791000},"page":"2068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7361","authenticated-orcid":false,"given":"Maryla","family":"Pelewicz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rymuza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-2337","authenticated-orcid":false,"given":"Katarzyna","family":"Pelewicz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-9015","authenticated-orcid":false,"given":"Piotr","family":"Mi\u015bkiewicz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, Natural History, Risk Factors, and Prevention of Graves\u2019 Orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_2","first-page":"747","article-title":"Graves\u2019 ophthalmopathy: Current concepts regarding pathogenesis and management","volume":"14","author":"Burch","year":"1993","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(91)90013-F","article-title":"Thyroid-associated eye disease: Pathophysiology","volume":"338","author":"Weetman","year":"1991","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jc.2011-0307","article-title":"Autoimmunity in Graves\u2019 ophthalmopathy: The result of an unfortunate marriage between TSH receptors and IGF-1 receptors?","volume":"96","author":"Wiersinga","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","article-title":"Pathogenesis of Graves\u2019 ophthalmopathy","volume":"329","author":"Bahn","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0161-6420(88)32978-7","article-title":"Dysthyroid optic neuropathy. The crowded orbital apex syndrome","volume":"95","author":"Neigel","year":"1988","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archopht.1981.03930010807002","article-title":"Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography","volume":"99","author":"Kennerdell","year":"1981","journal-title":"Arch. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2006.094607","article-title":"Clinical features of dysthyroid optic neuropathy: A European Group on Graves\u2019 Orbitopathy (EUGOGO) survey","volume":"91","author":"McKeag","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1450107","article-title":"Imaging in thyroid-associated orbitopathy","volume":"145","author":"Kahaly","year":"2001","journal-title":"Eur. J. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"Covelli","year":"2014","journal-title":"Thyroid"},{"key":"ref_14","first-page":"166","article-title":"Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy","volume":"67","author":"Rutkowska","year":"2016","journal-title":"Endokrynol. Pol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur. Thyroid J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1076\/orbi.20.4.275.2612","article-title":"Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy","volume":"20","author":"Kalmann","year":"2001","journal-title":"Orbit"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3341\/kjo.2012.26.2.73","article-title":"Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy","volume":"26","author":"Jeon","year":"2012","journal-title":"Korean J. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.20883\/medical.e519","article-title":"Impact of additional intravenous methylprednisolone pulse therapy on the quality of life in patients with dysthyroid optic neuropathy","volume":"90","author":"Pelewicz","year":"2021","journal-title":"J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_22","first-page":"1978590","article-title":"Influence of methylprednisolone pulse therapy on liver function in patients with graves\u2019 orbitopathy","volume":"2018","author":"Jankowska","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_23","first-page":"402","article-title":"Is high dose intravenous methylprednisolone pulse therapy in patients with Graves\u2019 orbitopathy safe?","volume":"65","author":"Kryczka","year":"2014","journal-title":"Endokrynol. Pol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:35Z","timestamp":1760136575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/8\/2068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["jcm11082068"],"URL":"https:\/\/doi.org\/10.3390\/jcm11082068","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}